Biotech and Pharmaceutical
News & Jobs
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  US Device


Market Summary

Company Profiles


Research Store

Biotech Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

Lundbeck Inc. 

Four Parkway North
Suite 200
Deerfield  Illinois  60015  U.S.A.
Phone: 800-455-1141 Fax: 847-282-1001

Lundbeck Inc. - Making a Difference One Patient at a Time

Headquartered in Deerfield, Illinois, with a portfolio of 17 specialty therapies and a pipeline of promising central nervous system (CNS) drugs, Lundbeck Inc. is committed to providing innovative therapies that fulfill unmet medical needs of people with CNS disorders and rare diseases for which few, if any, effective treatments are available.

As a wholly-owned subsidiary of H. Lundbeck A/S of Denmark, Lundbeck Inc. has a unique ownership structure. The company is 70 percent owned by the Lundbeck Foundation, which contributes millions annually to scientific research. In 2009, the Foundation granted more than $58 million to support research in biomedical and natural sciences.

Lundbeck Inc. offers the chance to make a difference while working in a unique and innovative environment. We are united by our passion and responsibility for helping the people with unmet medical needs. In addition to our extensive CNS pipeline that addresses a range of disorders from Alzheimer’s disease to Parkinson’s disease and depression, Lundbeck focuses on rare diseases with five orphan-designated therapies on the market and one more in late-stage development.

Our team of 350 pharmaceutical professionals, including an experienced team of clinical, regulatory and commercial experts, has a proven track record of working effectively with the U.S. Food and Drug Administration, developing and marketing high-need drugs that improve patients’ lives, and quickly and cost effectively bringing new products to market. Our operational excellence, diverse commercial portfolio and compelling development pipeline puts us in an excellent position for continued innovation and growth that will benefit patients for years to come.

At Lundbeck you can make a difference one patient at a time. If you wish to join a team where the challenges are great, the mission is meaningful and you can directly see the results of your hard work, Lundbeck may be the place for you.

 Key Statistics

Ownership: Public

Web Site: Lundbeck Inc.
Symbol: LUN.CO

 Company News
FDA Says OK To Review Of Lundbeck Inc. (LUN.CO)'s New Drug Application For Intravenous Carbamazepine 3/10/2014 8:32:33 AM    More...
Lundbeck Inc. (LUN.CO) Increases Its Share Capital By 65,992 Shares (0.0336 % Of Outstanding Shares) As A Result Of Employee Warrant Exercise 2/19/2014 9:04:10 AM    More...
Otsuka Pharmaceutical Co., Ltd. And Lundbeck Inc. (LUN.CO) To Present New Data On Brexpiprazole In Major Depressive Disorder (MDD) At European Psychiatry Association 2014 Congress 1/24/2014 6:52:59 AM    More...
Takeda Pharmaceuticals And Lundbeck Inc. (LUN.CO) Announce Brintellix® (Vortioxetine) For The Treatment Of Major Depressive Disorder In Adults Is Now Available In Pharmacies 1/23/2014 10:46:15 AM    More...
Ossianix Announces Strategic Research Collaboration With Lundbeck Inc. (LUN.CO) 1/7/2014 8:56:10 AM    More...
Lundbeck Inc. (LUN.CO) Wins EU Marketing Approval For Brintellix To Treat Adult Depression 1/3/2014 7:23:03 AM    More...
Lundbeck Inc. (LUN.CO) Scientists Part Of Group Achieving Breakthrough In Understanding Schizophrenia 12/20/2013 9:59:21 AM    More...
Lundbeck Inc. (LUN.CO)'s Ambition: Hopes To Launch New Alzheimer's Drug In 2017 12/17/2013 7:54:59 AM    More...
Lundbeck Inc. (LUN.CO) Release: New Study Showed Improvement In Cognitive Performance In Adult Patients Treated With Brintellix® (Vortioxetine) For Acute Episodes Of Major Depression 12/11/2013 7:40:44 AM    More...
Lundbeck Inc. (LUN.CO) And Otsuka Pharmaceutical Co., Ltd. To Co-Develop A Vaccine, Lu AF20513, Their Third Collaborative Development Project To Tackle Alzheimer’s Disease 12/11/2013 7:37:32 AM    More...